Google’s C2S-Scale 27B model generates a new cancer-immunotherapy hypothesis confirmed in living cells
Result confirmed
The takeaway
C2S-Scale 27B, a Gemma-based single-cell model, simulated over 4,000 drugs in two immune contexts.
Status
- Claim
Result confirmed
- Our reporting
- High confidence
- Verification
- Preprint only
- Importance
- 3 of 5
- Last verified
- 29 September 2026
Your AI and this story
- GPT-6 AstraIn its training data
- Claude Opus 5.5In its training data
- Gemini 4 HydrogenIn its training data
- Grok 4.7In its training data
It happened before the cutoffs of all four assistants, so it can be in their training data.
Key facts
- Virtual screen of >4,000 drugs in ‘immune-context-positive’ vs ‘-neutral’ settings
- Silmitasertib (CX-4945) + low-dose interferon: ~50% increase in antigen presentation in vitro
- In vitro only; no animal or clinical data; preprint
What happened
Researchers asked the model which drugs would amplify immune signals only in an immune-active context. Its top novel prediction held up in lab tests.
Why it matters
It is evidence that scaling biological foundation models can yield testable, novel hypotheses, though only in vitro so far.
Sources
2 sources from 2 sites. Numbers match the chips in the text.
2 sources: 1 primary, 1 press
Primary
- Google: How a Gemma model helped discover a new potential cancer therapy pathwayblog.google, official
Press
- DDW: Google AI model reveals new way to improve immunotherapyddw-online.com, press
Changes
- Filed